Clinical Cancer Research The Science of Cancer Health Disparities Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gregoire, L.
Right arrow Articles by Lancaster, W. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gregoire, L.
Right arrow Articles by Lancaster, W. D.
Clinical Cancer Research Vol. 7, 4280-4287, December 2001
© 2001 American Association for Cancer Research

Cancer Biology, Immunology, Cytokines

Spontaneous Malignant Transformation of Human Ovarian Surface Epithelial Cells in Vitro1

Lucie Gregoire, Raja Rabah, Eva-Maria Schmelz, Adnan Munkarah, Paul C. Roberts and Wayne D. Lancaster2

Department of Immunology and Microbiology [L. G., P. C. R.], Karmanos Cancer Institute [ L. G., E-M. S., A. M., W. D. L.], Departments of Pathology [R. R.] and Obstetrics and Gynecology [A. M., W. D. L.], and the Center for Molecular Medicine and Genetics [A. M., W. D. L.], Wayne State University School of Medicine, Detroit, Michigan 48201


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Purpose: Epithelial ovarian cancer has no reliable marker for early detection and no known specific premalignant changes. Human ovarian surface epithelial (HOSE) cells expressing human papillomavirus type 16 (HPV-16) E6/E7 genes undergo crisis, and surviving cells exhibit an immortalized phenotype. Cells show an increasingly invasive phenotype on collagen rafts over time. To ascertain the nature of this aberrant growth, we characterized this spontaneous progression of HOSE cells from a benign to an invasive phenotype using histopathology, immunophenotyping, and tumorigenesis assays.

Experimental Design: At various passages, cells were monitored for growth on collagen, response to tumor necrosis factor {alpha} and daunorubicin, immunohistochemistry and Western blot analysis of E-cadherin and ß-catenin, growth in soft agar, and tumor formation in immunodeficient mice.

Results: As passage number increased, cells became increasingly aggressive on collagen, with more pronounced focal stratification and invasion. Furthermore, late-passage cells were more resistant to the apoptotic effects of TNF-{alpha} and daunorubicin than earlier-passage cells. E-cadherin expression was limited to early-passage cells, whereas ß-catenin was expressed regardless of passage. Cells invading collagen formed colonies in soft agar at low efficiency but were not tumorigenic in immunodeficient mice. Some cultures recovered from colonies grew in soft agar at high efficiencies, and one was tumorigenic.

Conclusions: HOSE cells expressing E6/E7, over time, develop characteristics of malignant cells and produce tumors consistent with an ovarian surface epithelium lineage. Progression of HOSE cells from a benign to an invasive phenotype in vitro may provide a model to dissect the progression of ovarian cancer.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Although ovarian cancers are less common than other gynecological tumors, they account for a disproportionate number of fatal cases, being responsible for almost one-half of the deaths from all female genital tract tumors. This is caused, in part, by the decline in the incidence and mortality of advanced cervical and endometrial cancers since the wide use of screening techniques that aid in early detection. In addition, most women with ovarian cancer tend to present with advanced and disseminated disease that is more difficult to manage and often fatal. Currently, little is known about the pathogenesis of sporadic ovarian cancer development, and no screening methods for early detection are available.

Most epithelial cell cancers (cervix, colon, skin, prostate, breast, etc.) develop from precursor lesions that arise from an accumulation of mutations. Cervix cancer develops through a continuum of well-defined stages of intraepithelial neoplasia to invasive disease. These stages have been reproduced in vitro with a high degree of fidelity (1 , 2) . Such precursor lesions have not been identified for ovarian cancer, but it has been proposed that ovarian cancers arise by a multistep process through increasingly aggressive stages (3) . Some histopathological studies have shown an increased incidence of ovarian surface epithelium aberrations in ovaries from women with a family history of ovarian cancer compared with ovaries from normal women (4) ; however, this has not been a consistent finding (5 , 6) . Others have reported similar aberrations in normal ovaries of ovarian cancer patients, suggesting these to be precursor lesions (7) . There is, however, no evidence that the changes seen in the surface epithelium are precursors to epithelial ovarian cancer.

Progress in the cultivation of HOSE3 cells has provided a limited model to study the growth characteristics of this epithelium in vitro; however, primary HOSE cells undergo a restricted number of population doublings before senescence (8 , 9) . Introduction of the SV40 T-antigen or HPV-16 E6/E7 genes extends the life span of these cells (10 , 11) . These cells undergo crisis, and after several months, continuously growing cells emerge that seem to have an unlimited life span fail to form colonies in soft agar and are not tumorigenic in immunodeficient mice. We report here, however, that HPV-16 E6/E7-immortalized HOSE cells develop a progressively aggressive phenotype over time when monitored by three-dimensional organotypic culture on collagen rafts. Later passages of these cells readily stratify, form nodules, and invade the collagen gel. This coincides with their ability to form colonies in soft agar and develop resistance to the cytotoxic effects of TNF-{alpha} and daunorubicin; however, these cells fail to form tumors in SCID mice. Notwithstanding, some cultures derived from the soft agar colonies can produce aggressive, poorly differentiated tumors in SCID mice.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Culture.
The culturing of primary HOSE cells, HOSE-A (96.9.18) and HOSE-B (1.24.96), and extension of their life span by infection with the amphotropic retrovirus LXSN-16E6E7 and organotypic culture of HOSE cells grown on collagen with fibroblast feeder cells has been described previously (12) . For histopathological analysis of organotypic cultures, the collagen rafts were overlayed with 2% agarose in RPMI 1640 at 46°C, allowed to gel to stabilize the raft, and transferred to 10% buffered formalin for processing for routine histopathology. Postcrisis 96.9.18 and 1.24.96 cells were maintained as monolayer cultures on standard plastic tissue culture vessels and passed at a 1:10 split ratio at the time of confluence. Passage numbers referred to in the text are the numbers of passages the cells have undergone since crisis.

Growth in Soft Agar.
Cells (2 x 104) were suspended in 1 ml RPMI 1640 containing 20% FCS and mixed with 1 ml of 0.7% Bactoagar (Difco Laboratories, Detroit, MI) in RPMI 1640 at 45°C and layered over 5 ml of 0.75% Bactoagar in RPMI 1640 in 60-mm dishes and cultured in 5% CO2 in a humidified chamber. Colonies were counted 3 weeks after seeding, and their size was determined using a x10 calibrated eyepiece. Colonies were separated into two groups: (a) >=50 µm; and (b) >=10 but <50 µm. Human ovarian cancer cell line SKOV-3 was used as control.

In Vivo Tumorigenicity Assays.
Female (4–6 weeks of age) SCID beige mice were obtained from Charles Rivers, Wilmington, MA. Cells were grown to confluency in monolayer, trypsinized, washed, and resuspended in sterile PBS at a concentration of 1 x 107 cells/ml. Each mouse was inoculated with 0.3 ml of cell suspension s.c. on the flank and i.p. Mice were weighed and inspected for tumor growth or ascites for a period up to 8 months before terminating the experiment. Animal care was in accordance with the Wayne State University (Detroit, MI) Division of Laboratory Animal Research guidelines.

Viability Assays.
Cells (8 x 103) were seeded onto 96-well dishes and incubated overnight. Cells were treated for 2 h with daunorubicin hydrochloride in PBS (0 to 1.0 µM; Sigma Chemical Co., St. Louis, MO), after which the medium was removed, fresh medium was added, and the cells were incubated for an additional 22 h. Cells treated with TNF-{alpha} (0 to 10 ng/ml; Sigma Chemical Co.) were incubated for 24 h. Viability was evaluated by the conversion of tetrazolium bromide to formazan by viable cells [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay] as described by Hansen et al. (13) . Differences in viability were calculated using Bonferoni’s multiple comparison test after ANOVA analysis, and Ps <0.05 were considered significant.

Analysis of Proteins.
Western blot analysis for detection of E-cadherin and ß-catenin in cell lysates were as described previously. Cells were scraped off the plates, and lysed with a hypotonic lysis buffer (1 mM NaCO3, 0.2 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, and 1 µg/ml pepstatin) for 30 min on ice. After passing through a 20-gauge needle (10 times), the lysates were centrifuged (2,000 x g for 5 min) and the supernatants were removed and centrifuged at 4°C for 30 min at 15,000 x g (14 , 15) . Protein concentrations were determined by a bicinchoninic acid protein assay kit (Sigma Chemical Co.). Proteins (20 µg/well) were separated on a 12.5% SDS-polyacrylamide gel and transferred to nitrocellulose; ß-actin staining was used as the loading control. Membranes were immunoblotted using monoclonal antibodies against E-cadherin (clone HECD-1; Zymed Laboratories, San Francisco, CA) or anti-E-cadherin, (Santa Cruz Biotechnology, Santa Cruz, CA), ß-catenin (clone 15B8; Sigma Chemical Co.), and horseradish peroxidase-conjugated secondary antibodies (Sigma Chemical Co.). Bands were visualized by treatment with a chemiluminescent substrate (LumiGLO, Kirkegaard & Perry Laboratories, Gaithersburg, MD) and recorded on Fuji X-ray film. A431 cells were used as positive control. Immunohistochemical staining was done on 3–5-µm sections that were deparaffinized in xylene and rehydrated through graded alcohol. After blocking for 1 h at room temperature with 2% bovine calf serum in PBS containing 0.5% delipidated milk powder, the sections were incubated overnight at 4°C with primary antibodies anti-vimentin (clone V9; Sigma Chemical Co.), anti-Pan cytokeratin (Sigma Chemical Co.) polyclonal anti-ß-catenin antibody (Sigma Chemical Co.), monoclonal anti-E-cadherin antibody (clone HECD-1; Zymed) and monoclonal anti-CA125 (clone M11; Dako, Carpinteria, CA) and then rinsed with PBS and incubated with fluorochrome-conjugated secondary antibodies and 4',6-diamidino-2-phenylindole (1 ng/ml) to stain nuclei (Molecular Probes, Eugene, OR) for 1 h. In some instances, 2% goat serum was used to block nonspecific binding reactions. After intensive washes with PBS, the sections were mounted with Mowiol (Calbiochem, La Jolla, CA) supplemented with 0.2% 1,4-diaza bicyclo-[2.2.2]-octane (Sigma Chemical Co.) as antifade and evaluated with a NIKON E800 epifluorescence microscope with differential interference contrast optics. Images were optically captured with a SenSys digital charged coupled device camera using ISEE imaging software (Inovision, Raleigh, NC). Images from samples using nonspecific antibody (mouse monoclonal IgG1; BD Pharmigen, San Diego, CA) and/or only secondary antibody served as controls.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Characteristics of HOSE Cells.
Previously we have reported the growth of primary and extended-life span HOSE cells in organotypic culture (12) . In our hands, 96.9.18 (previously termed HOSE-A) and 1.24.96 (previously termed HOSE-B) transduced with HPV-16 E6/E7 underwent about 20 population doublings before the cells abruptly stopped replicating (crisis). Cultures were maintained with fresh medium changes biweekly for about 3 (96.9.18) to 12 (1.24.96) months, when cells began to replicate. These cells were expanded, and both cultures have undergone >120 passages at a split ratio of 1:10 and are likely immortalized. Both 96.9.18 and 1.24.96 maintain a cobblestone appearance in monolayer culture similar to precrisis cells, as depicted in Fig. 1Citation . These cells continue to express HPV-specific transcripts (data not shown) as shown previously by others for HPV oncogene-transduced HOSE cells (11) .



View larger version (220K):
[in this window]
[in a new window]
  		Fig. 1. Morphology of 96.9.18 HOSE cells at passage 89 grown in monolayer culture (x10).

 
Organotypic Culture.
Both 96.9.18 and 1.24.96 primary cultures grew as a monolayer on collagen rafts, but extended-life span cells stratified into 2–4-cell thick layers; however their phenotypes in monolayer culture were similar (12) . Regardless of passage, postcrisis cells maintained similar phenotypes in monolayer. Because previously we had observed phenotypic changes when cells were grown on collagen rafts, we tested the phenotype of postcrisis cells at various passages. Early-passage (10–30 passages) postcrisis cells grown on collagen showed a single-cell layer phenotype with only focal stratification (Fig. 2, A and B)Citation . Intermediate-passage cells (40–70 passages) grew as a monolayer on collagen but with increased areas of focal stratification. Of interest is the occasional presence of cells embedded within the collagen (Fig. 2, C and D)Citation . Late-passage cells (>70 passages) showed, in addition to the monolayer pattern, distinct nodules of large epithelioid cells with hyperchromatic, pleomorphic nuclei, and small nucleoli with abundant vacuolated and amphophilic cytoplasm (Fig. 2, E and F)Citation . Some of the nodules formed small papillary structures, and others aggressively invaded the underlying collagen with wide margins reminiscent of peritoneal implants of serous ovarian carcinoma (Fig. 2, G and H)Citation . The cells stained positive for both keratin and vimentin, indicating their ovarian surface epithelial origin (data not shown; Ref. 16 ). Numerous mitotic figures were seen, and many were atypical. Karyorrhexis was also abundant.



View larger version (80K):
[in this window]
[in a new window]
  		Fig. 2. H&E-stained sections of organotypic cultures of postcrisis HOSE cells. 96.9.18 at low- (A), intermediate- (C), and high- (E) passage and 1.24.96 at low- (B), intermediate- (D), and high- (F) passage (x40). High-passage 96.9.18 (G) and 1.24.96 (H) at low power magnification (x10).

 
Growth in Soft Agar.
Both early- and intermediate-passage 96.9.18 and 1.24.96 cells were unable to form colonies in soft agar. Human ovarian cancer cell line SKOV-3 readily formed large (>50-µm) colonies in soft agar. Late-passage 96.9.18 and 1.24.96 cells were also capable of forming >50-µm colonies in soft agar but at diminished efficiency compared with SKOV-3. In addition, both cell cultures also gave rise to smaller colonies at higher efficiency (Table 1)Citation . A number of large colonies were selected from the soft agar, but only cells from 96.9.18 colonies grew (designated LC1-LC4). Retesting these cells in soft agar after expansion revealed the cultures possessed pleomorphic phenotypes with respect to colony-forming efficiency and colony size (Table 1)Citation .


View this table:
[in this window]
[in a new window]
  		Table 1 HOSE cell colony formation in soft agar and tumorigenicity in SCID mice

 
In Vivo Tumorigenicity Assays.
None of the late-passage monolayer-derived cultures formed tumors in SCID mice when 3 x 106 cells were injected either i.p. or s.c. within 8 months, whereas 3 x 106 SKOV-3 cells produced tumors at injected sites in 3–4 weeks. Cultures LC2 and LC3 were also tested for tumor formation in SCID mice. LC2 produced tumors at 2 of 2 sites (s.c. and also i.p.), with 3 x 106 cells at each site within 8 weeks with no evidence of ascites; no tumors were detected in 10 weeks in the mouse injected with 3 x 106 LC3 cells. The s.c. and peritoneal tumor nodules produced in the mouse injected with LC2 were made up of epithelial cells that showed focal glandular differentiation and numerous mitotic figures. The cells were large, had pleomorphic and hyperchromatic nuclei with prominent nucleoli, and abundant vacuolated and amphophilic cytoplasm (Fig. 3)Citation . There was strong cytoplasmic staining with broad-spectrum antikeratin and anti-vimentin antibodies, similar to the known immunophenotypic staining of epithelial ovarian tumors (data not shown; Ref. 16 ).



View larger version (114K):
[in this window]
[in a new window]
  		Fig. 3. Histopathology of i.p. tumor from SCID mouse injected with LC2. A, large tumor cells are seen infiltrating adjacent pancreatic tissue (x20). B, poorly differentiated large tumor cells with focal glandular formation (arrow; x40).

 
Viability Assays.
Postcrisis cells from 1.24.96 (low and high passage) and 96.9.18 (intermediate and high passage) were tested for their sensitivity to the cytotoxic agent TNF-{alpha} and daunorubicin, a chemotherapeutic agent. Late-passage (p105) cells from 1.24.96 were significantly more resistant to the cytotoxic effects of daunorubicin and TNF-{alpha} than the early (p33)-passage cells (P < 0.001; Fig. 4ACitation ). Only at the highest concentration of daunorubicin tested did the high-passage cells show a difference to untreated cells (P < 0.001). Likewise, the resistance of 96.9.18 high-passage cells (p121) was significantly greater than intermediate (p55)-passage cells (P < 0.001). As with 1.24.96 high-passage cells, 96.9.18 high-passage cells showed sensitivity at the highest concentration of daunorubicin tested. Only the intermediate-passage 96.9.18 cells showed sensitivity to TNF-{alpha} when compared with untreated cells, whereas high passage cells were resistant to TNF-{alpha} (Fig. 4B)Citation .



View larger version (44K):
[in this window]
[in a new window]
  		Fig. 4. Viability of 1.24.96 cells (A) and 96.9.18 cells (B) treated with TNF-{alpha} and daunorubicin.

 
Analysis of Proteins.
Recent reports have suggested that the levels and/or localization of ß-catenin and E-cadherin may be linked to tumor cell progression and invasiveness. To determine whether there were any direct correlations between ß-catenin and E-cadherin expression and/or subcellular localization and the passage number of our HOSE cells, we analyzed the cells by Western blot analysis and indirect immunofluorescence assay.

Immunohistochemical staining of both cell cultures showed no evidence of E-cadherin staining from cells grown on collagen rafts or in monolayer culture. In contrast, positive membrane staining of SKOV-3 cells on collagen rafts was observed, albeit very weak, when probed with anti-E-cadherin antibody. These results were not confirmed by Western blot analysis of the isolated membrane fractions of these cells. Detectable levels of E-cadherin were only observed in the earliest passages of postcrisis 1.24.96 cells tested (p38 and less in p78) but not in 96.9.18 cells. It should be noted that detection was only possible in 1.24.96 cells when 50 µg of protein was probed (Fig. 5)Citation . Cytosolic E-cadherin was not detected in either HOSE culture regardless of passage number.



View larger version (79K):
[in this window]
[in a new window]
  		Fig. 5. Western blot analysis for ß-catenin and E-cadherin. The membrane fraction (top two panels) was immunoblotted for ß-catenin (first panel) and ß-actin (second panel). The cytoplasmic fraction was immunoblotted for ß-catenin (third panel) and ß-actin (fourth panel). The bottom panel is an E-cadherin immunoblot of 1.24.96 cells at the indicated passages.

 
Western blot analysis of ß-catenin expression revealed both a membrane and cytosolic localization (Fig. 5)Citation . There was no significant change in the amount of cytosolic ß-catenin with respect to cell passage in either cell culture. ß-catenin positive degradation bands were evident in the cytosolic fractions, suggesting that ß-catenin is being degraded in the cytosol. The ratio between ß-catenin and ß-actin staining showed little or no change in levels during the transition to the malignant phenotype (Fig. 5)Citation . Although the ratios of ß-catenin/ß-actin seemed high in 96.8.18 cells at p69 and seemed to increase in 1.24.96 cells with passage number, these were not consistent findings. Indirect immunofluorescence assay analysis of raft cultures showed similar levels of cytosolic and membrane-associated ß-catenin staining regardless of passage number (data not shown).


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Previously we have shown that HPV-16 E6/E7 gene expression in primary HOSE cells results in an extended life span and aberrant growth in organotypic culture (12) . The use of viral oncogenes to disrupt cell cycle regulation is likely a valid approach to modify HOSE cell behavior. This rationale is based on the high frequency of p16INK4/MTS1 dysregulation in early stage ovarian cancers (17 , 18) . The p16 tumor suppressor gene is a cdk inhibitor that decelerates the cell cycle by inactivating the cdks that phosphorylate the retinoblastoma tumor suppressor gene protein (pRB). pRB acts by binding and inhibiting the cellular transcription factor E2F, among others. Phosphorylation of pRB by cdks leads to release of E2F, which mediates progression through the cell cycle. HPV-16 E7 binds to pRB and dissociates the E2F-pRB complex (19) . The effect is similar to the dysregulation of p16INK4/MTS1 gene expression, the effect of which also abrogates the binding of E2F by pRB. Similarly, p53 is frequently mutated in early ovarian cancers, suggesting that this gene may contribute to the development of ovarian cancers (20 , 21) . HPV-16 E6 binds to and promotes the ubiquitin-mediated degradation of p53. Thus, E7 and E6 expression would likely create a similar and appropriate premalignant platform as that created by loss of p16 and p53 function, respectively, in HOSE cells in vivo.

HOSE cells transduced with HPV-16 E6/E7 enter crisis within a few population doublings. Here, we report the growth characteristics in organotypic culture of HOSE cells derived from two different patients that survived crisis. Both cell cultures underwent, over time, three distinct phases of growth on collagen, exhibiting: (a) no invasion with rare focal stratification; (b) single-cell invasion with focal stratification; and (c) robust stratification with papillary formation and intense invasion of the collagen bed. Furthermore, the stage of development of the invasive phenotype on collagen paralleled the ability of the cells to form colonies in soft agar. This progression to an invasive phenotype was dependent on the number of population doublings, because both HOSE cultures exhibited the phenotype at roughly the same number of passages. Human keratinocytes expressing high-risk HPV E6/E7 genes also grow aberrantly on collagen rafts (1) . These cells recapitulate the continuum of cellular changes that represent the transition at early passage from mild to moderate to severe dysplasia/carcinoma in situ at late passage. Cells eventually become tumorigenic in nude mice after many months in culture (22) .

The lack of tumorigenicity of late-passage HOSE cells that show the invasive phenotype on collagen may be attributable to heterogeneity within the cell population, which thus limits the number of truly malignant cells. This is supported by the ability of cells derived from some colonies formed in soft agar to produce tumors in SCID mice, whereas cells from other colonies showed low colony-forming efficiency and were not tumorigenic. This is not surprising, because tumor cells are genetically heterogeneous (23) .

With increased passage numbers, the sensitivity of both ovarian cell lines to daunorubicin, a chemotherapeutic agent, and TNF-{alpha}, a multifactorial cytokine, is significantly reduced. These two compounds were used because both induce apoptosis in cell lines but use different cell death signaling pathways. Daunorubicin, an anthracyclin widely used as an antitumor agent, causes DNA damage and induces apoptosis, the latter possibly an independent pathway involving the generation of reactive oxygen species, ceramide synthesis, and the activation of c-Jun NH2-terminal kinase (24 , 25) . TNF-{alpha} is an important mediator of inflammation, but has also been shown to induce apoptosis in some cell lines by binding to the TNF receptors and in epithelial cells, mostly the p60 receptor (26) , thereby activating the apoptotic cascade. It has been shown, however, that TNF-{alpha} selectively inhibits proliferation of epithelial cells derived from normal cervix, normal ovarian epithelium, keratinocytes, or myeloid cells but has no effect or even stimulates cell growth in immortal, dedifferentiated, or malignant cells (27, 28, 29, 30, 31) . This correlates well with our findings that cytotoxicity of TNF-{alpha} or daunorubicin is restricted to lower noninvasive passages of HOSE cells, whereas those passages with a more malignant phenotype are resistant. Furthermore, it has been shown that sensitive immortalized keratinocytes do not form tumors in nude mice, but nonsensitive cells are tumorigenic (32) .

Apoptosis has been shown to play an important role in the regulation or limitation of cell populations. Disruption of apoptotic pathways has been implicated in tumor formation and metastasis and may account for the uncontrolled cell proliferation (33, 34, 35) . It has yet to be determined whether mutations in tumor suppressor proteins, expression of oncogenes, or development of multidrug resistance or a specific resistance to daunorubicin (by inactivation of the active compound Ref. 36 ) or TNF-{alpha} (by releasing endogenous soluble type I TNF-{alpha} receptor Ref. 37 ) play a role in the differences in HOSE cell sensitivity.

ß-catenin is a cell adhesion protein, primarily localized at the junctional complexes in the lateral membranes bound to E-cadherin. Cytosolic ß-catenin is rapidly ubiquinated and degraded in the proteasomes. A disruption of this pathway had been described extensively in colonic tumors that carry an adenomatous polyposis coli mutation or truncation of ß-catenin. However, the disruption of the adenomatous polyposis coli-ß-catenin pathway seems to be involved in a variety of other cancers (38) . It has been shown that mutations to ß-catenin do occur within the phosphorylation sites on the NH2 terminus, preventing ubiquitination and degradation, in ovarian cancers, but seem to be limited to ovarian endometrioid tumors (39) . Such mutations stabilize ß-catenin for interaction with the T-cell factor family of transcription factors for nuclear transport and transactivation of a number of genes, most notably c-myc and cyclin D1 (38) . ß-catenin expression in cytosolic fractions were similar in all passage levels of the HOSE cells, confirming reports that the expression of cytosolic ß-catenin is an early event in carcinogenesis (39) . Whether this protein plays a role in malignant transformation of the cells is unknown.

The progressive loss of E-cadherin expression from early- (noninvasive) to late- (invasive) passage HOSE cells correlates well with recent findings that the loss of E-cadherin is not only associated with increased invasiveness of tumor cells, but also that these changes may be an early event in carcinogenesis (40) . Using immunocytochemistry, Darai et al. (41) showed that E-cadherin expression was homogeneous in benign ovarian tumors but was heterogeneously expressed or undetectable in most borderline and malignant tumors. Davies et al. (42) showed, also by immunocytochemistry, that only one of five ovarian cancer cell lines and 56% of ovarian cancers expressed E-cadherin at appreciable levels. In addition, the majority of poorly differentiated tumors were E-cadherin-negative. Forced expression of murine E-cadherin in SV40 large T-antigen immortalized HOSE cells (which normally express a fibroblastic phenotype in monolayer and are keratin negative and nontumorigenic) induces a differentiated epithelial phenotype (43) . These cells now are tumorigenic in SCID mice and produce poorly differentiated adenocarcinomas (44) . Murine E-cadherin was expressed at high levels in monolayer cell cultures and was detectable in resultant mouse tumors by immunofluorescence. The discrepancy in expression of E-cadherin between these cells and invasive 1.24.96 cells may be attributable to the heterogeneous nature of epithelial ovarian cancer, which may be reflected in differential gene expression. For example, K-ras overexpression is almost limited to mucinous ovarian cancer (45) .

Efforts have focused on understanding the role of various known oncogenes, tumor suppressor genes, and cytological aberrations that might contribute to ovarian carcinogenesis. However, most studies have dealt with carcinomas, and it is unknown whether chromosomal or gene expression changes are the result or have a causal relationship to the cancer. This paper demonstrates the spontaneous progression of HOSE cells from a benign to an invasive phenotype using histopathology, immunophenotyping, and tumorigenesis assays. We propose that intermediate in this transition is a putative preneoplastic lesion that undergoes genetic changes leading to the invasive phenotype. Analysis of chromosomal or gene expression changes throughout the continuum described here should provide insights into the nature of this transition and yield valuable information that would help explain the steps leading to ovarian carcinogenesis.


   ACKNOWLEDGMENTS
 
We thank Dr. John Lechner for critical reading of the manuscript.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by grants from the Gail Purtan Ovarian Cancer Research Fund of the Karmanos Cancer Institute and the Department of Obstetrics and Gynecology of Wayne State University and the National Institutes of Health. Back

2 To whom requests for reprints should be addressed, at Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, 540 East Canfield Avenue, Room 3248, Detroit, MI 48201. Phone: (313) 577-0028; Fax: (313) 577-5218; E-mail: wayne{at}cmb.biosci.wayne.edu Back

3 The abbreviations used are: HOSE, human ovarian surface epithelial; HPV-16, human papillomavirus type 16; TNF-{alpha}, tumor necrosis factor {alpha}; SCID, severe combined immunodeficiency; cdk, cyclin-dependent kinase; pRB, retinoblastoma protein. Back

Received 5/ 8/01; revised 8/27/01; accepted 8/31/01.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. McCance D. J., Kopan R., Fuchs E., Laimins L. A. Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proc. Natl. Acad. Sci. USA, 85: 7169-7173, 1988.[Abstract/Free Full Text]
  2. Rader J. S., Golub T. R., Hudson J. B., Patel D., Bedell M. A., Laimins L. A. In vitro differentiation of epithelial cells from cervical neoplasias resembles in vivo lesions. Oncogene, 5: 571-576, 1990.[Medline]
  3. Link C. J., Jr., Kohn E., Reed E. The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: epidemiologic, pathologic, and molecular aspects. Gynecol. Oncol., 60: 347-354, 1996.[CrossRef][Medline]
  4. Salazar H., Godwin A. K., Daly M. B., Laub P. B., Hogan W. M., Rosenblum N., Boente M. P., Lynch H. T., Hamilton T. C. Microscopic benign and invasive malignant neoplasms and a cancer- prone phenotype in prophylactic oophorectomies. J. Natl. Cancer Inst. (Bethesda), 88: 1810-1820, 1996.[Abstract/Free Full Text]
  5. Stratton J. F., Buckley C. H., Lowe D., Ponder B. A. Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. J. Natl. Cancer Inst. (Bethesda), 91: 626-628, 1999.[Abstract/Free Full Text]
  6. Werness B. A., Afify A. M., Bielat K. L., Eltabbakh G. H., Piver M. S., Paterson J. M. Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. Hum. Pathol., 30: 151-157, 1999.[CrossRef][Medline]
  7. Scully R. E. Pathology of ovarian cancer precursors. J. Cell Biochem. Suppl., 23: 208-218, 1995.[Medline]
  8. Kruk P. A., Maines-Bandiera S. L., Auersperg N. A simplified method to culture human ovarian surface epithelium. Lab. Investig., 63: 132-136, 1990.[Medline]
  9. Elliott W. M., Auersperg N. Growth of normal human ovarian surface epithelial cells in reduced-serum and serum-free media. In Vitro Cell. Dev. Biol., 29A: 9-18, 1993.
  10. Maines-Bandiera S. L., Kruk P. A., Auersperg N. Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenic responses to extracellular matrix. Am. J. Obstet. Gynecol., 167: 729-735, 1992.[Medline]
  11. Tsao S. W., Mok S. C., Fey E. G., Fletcher J. A., Wan T. S., Chew E. C., Muto M. G., Knapp R. C., Berkowitz R. S. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp. Cell Res., 218: 499-507, 1995.[CrossRef][Medline]
  12. Gregoire L., Munkarah A., Rabah R., Morris R. T., Lancaster W. D. Organotypic culture of human surface epithelial cells: a potential model for ovarian carcinogenesis. In Vitro Cell. Dev. Biol. Anim., 34: 636-639, 1998.[Medline]
  13. Hansen M. B., Nielsen S. E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods, 119: 203-210, 1989.[CrossRef][Medline]
  14. Giarre M., Semenov M. V., Brown A. M. Wnt signaling stabilizes the dual-function protein ß-catenin in diverse cell types. Ann. NY Acad. Sci., 857: 43-55, 1998.[Abstract/Free Full Text]
  15. Kimura Y., Shiozaki H., Doki Y., Yamamoto M., Utsunomiya T., Kawanishi K., Fukuchi N., Inoue M., Tsujinaka T., Monden M. Cytoplasmic ß-catenin in esophageal cancers. Int. J. Cancer, 84: 174-178, 1999.[CrossRef][Medline]
  16. Putts J. J., Vooijs G. P., Huysmans A., van Aspertm A., Ramaekers F. C. Cytoskeletal proteins as tissue-specific markers in cytopathology. Exp. Cell Biol., 54: 73-79, 1986.[Medline]
  17. Milde-Langosch K., Ocon E., Becker G., Loning T. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int. J. Cancer, 79: 61-65, 1998.[CrossRef][Medline]
  18. Suh S. I., Cho J. W., Baek W. K., Suh M. H., Carson D. A. Lack of mutation at p16INK4A gene but expression of aberrant p16INK4A RNA transcripts in human ovarian carcinoma. Cancer Lett., 153: 175-182, 2000.[CrossRef][Medline]
  19. Chellappan S., Kraus V. B., Kroger B., Munger K., Howley P. M., Phelps W. C., Nevins J. R. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc. Natl. Acad. Sci. USA, 89: 4549-4553, 1992.[Abstract/Free Full Text]
  20. Skomedal H., Kristensen G. B., Abeler V. M., Borresen-Dale A. L., Trope C., Holm R. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas. J. Pathol., 181: 158-165, 1997.[CrossRef][Medline]
  21. Kupryjanczyk J., Bell D. A., Dimeo D., Beauchamp R., Thor A. D., Yandell D. W. p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum. Pathol., 26: 3873-3892, 1995.
  22. Hurlin P. J., Kaur P., Smith P. P., Perez-Reyes N., Blanton R. A., McDougall J. K. Progression of human papillomavirus type 18-immortalized human keratinocytes to a malignant phenotype. Proc. Natl. Acad. Sci. USA, 88: 570-574, 1991.[Abstract/Free Full Text]
  23. Rubin H. The significance of biological heterogeneity. Cancer Metastasis Rev., 9: 1-20, 1990.[CrossRef][Medline]
  24. Jaffrezou J. P., Levade T., Bettaieb A., Andrieu N., Bezombes C., Maestre N., Vermeersch S., Rousse A., Laurent G. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J., 15: 2417-2424, 1996.[Medline]
  25. Mansat-de Mas V., Bezombes C., Quillet-Mary A., Bettaieb A., D’orgeix A. D., Laurent G., Jaffrezou J. P. Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation and apoptosis induced by daunorubicin. Mol. Pharmacol., 56: 867-874, 1999.[Abstract/Free Full Text]
  26. Brockhaus M., Schoenfeld H. J., Schlaeger E. J., Hunziker W., Lesslauer W., Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc. Natl. Acad. Sci. USA, 87: 3127-3131, 1990.[Abstract/Free Full Text]
  27. Bettaieb A., Record M., Come M. G., Bras A. C., Chap H., Laurent G., Jaffrezou J. P. Opposite effects of tumor necrosis factor {alpha} on the sphingomyelin-ceramide pathway in two myeloid leukemia cell lines: role of transverse sphingomyelin distribution in the plasma membrane. Blood, 88: 1465-1472, 1996.[Abstract/Free Full Text]
  28. Woodworth C. D., McMullin E., Iglesias M., Plowman G. D. Interleukin 1 {alpha} and tumor necrosis factor {alpha} stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Proc. Natl. Acad. Sci. USA, 92: 2840-2844, 1995.[Abstract/Free Full Text]
  29. Powell C. B., Herzog T. J., Scott J. H., Collins J. L. Evidence for a protein synthesis-dependent and -independent TNF {alpha} cytolytic mechanism. Gynecol. Oncol., 58: 327-335, 1995.[CrossRef][Medline]
  30. Villa L. L., Vieira K. B., Pei X. F., Schlegel R. Differential effect of tumor necrosis factor on proliferation of primary human keratinocytes and cell lines containing human papillomavirus types 16 and 18. Mol. Carcinog., 6: 5-9, 1992.[Medline]
  31. Higuchi M., Aggarwal B. B. Differential roles of two types of the TNF receptor in TNF-induced cytotoxicity. DNA fragmentation, and differentiation. J. Immunol., 152: 4017-4025, 1994.[Abstract]
  32. Malejczyk J., Malejczyk M., Majewski S., Breitburd F., Luger T. A., Jablonska S., Orth G. Increased tumorigenicity of human keratinocytes harboring human papillomavirus type 16 is associated with resistance to endogenous tumor necrosis factor-{alpha}-mediated growth limitation. Int. J. Cancer, 56: 593-598, 1994.[Medline]
  33. Vogelstein B., Kinzler K. W. The multistep nature of cancer. Trends Genet., 9: 138-141, 1993.[CrossRef][Medline]
  34. Thompson C. B. Apoptosis in the pathogenesis and treatment of disease. Science (Wash. DC), 267: 1456-1462, 1995.[Abstract/Free Full Text]
  35. Wyllie A. H. Apoptosis and carcinogenesis. Eur. J. Cell Biol., 73: 189-197, 1997.[Medline]
  36. Ax W., Soldan M., Koch L., Maser E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem. Pharmacol., 59: 293-300, 2000.[CrossRef][Medline]
  37. Malejczyk J., Malejczyk M., Breitburd F., Majewski S., Schwarz A., Expert-Besancon N., Jablonska S., Orth G., Luger T. A. Progressive growth of human papillomavirus type 16-transformed keratinocytes is associated with an increased release of soluble tumour necrosis factor (TNF) receptor. Br. J. Cancer, 74: 234-239, 1996.[Medline]
  38. Morin P. J. ß-catenin signaling and cancer. Bioessays, 21: 1021-1030, 1999.[CrossRef][Medline]
  39. Palacios J., Gamallo C. Mutations in the ß-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res., 58: 1344-1347, 1998.[Abstract/Free Full Text]
  40. Behrens J. Cadherins and catenins: role in signal transduction and tumor progression. Cancer Metastasis Rev., 18: 15-30, 1999.[CrossRef][Medline]
  41. Darai E., Scoazec J. Y., Walker-Combrouze F., Mlika-Cabanne N., Feldmann G., Madelenat P., Potet F. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum. Pathol., 28: 922-928, 1997.[CrossRef][Medline]
  42. Davies B. R., Worsley S. D., Ponder B. A. Expression of E-cadherin, {alpha}-catenin and ß-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology, 32: 69-80, 1998.[CrossRef][Medline]
  43. Auersperg N., Pan J., Grove B. D., Peterson T., Fisher J., Maines-Bandiera S., Somasiri A., Roskelley C. D. E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc. Natl. Acad. Sci. USA, 96: 6249-6254, 1999.[Abstract/Free Full Text]
  44. Ong A., Maines-Bandiera S. L., Roskelley C. D., Auersperg N. An ovarian adenocarcinoma line derived from SV40/E-cadherin-transfected normal human ovarian surface epithelium. Int. J. Cancer, 85: 430-437, 2000.[CrossRef][Medline]
  45. Enomoto T., Weghors C. M., Inoue M., Tanizawa O., Rice J. M. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am. J. Pathol., 139: 777-785, 1991.[Abstract]



This article has been cited by other articles:


Home page
 CarcinogenesisHome page
G. Yang, D. G. Rosen, I. Mercado-Uribe, J. A. Colacino, G. B. Mills, R. C. Bast Jr, C. Zhou, and J. Liu
Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells
Carcinogenesis, January 1, 2007; 28(1): 174 - 182.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
A. B. Alvero, D. A. Fishman, M. B. Qumsiyeh, M. Garg, B. M. Kacinski, and E. Sapi
Telomerase Prolongs the Lifespan of Normal Human Ovarian Surface Epithelial Cells Without Inducing Neoplastic Phenotype
Reproductive Sciences, December 1, 2004; 11(8): 553 - 561.
[Abstract] [PDF]

Home page
 Ann OncolHome page
C. Faleiro-Rodrigues, I. Macedo-Pinto, D. Pereira, and C. S. Lopes
Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas
Ann. Onc., October 1, 2004; 15(10): 1535 - 1542.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Liu, G. Yang, J. A. Thompson-Lanza, A. Glassman, K. Hayes, A. Patterson, R. T. Marquez, N. Auersperg, Y. Yu, W. C. Hahn, et al.
A Genetically Defined Model for Human Ovarian Cancer
Cancer Res., March 1, 2004; 64(5): 1655 - 1663.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. K. Zorn, A. A. Jazaeri, C. S. Awtrey, G. J. Gardner, S. C. Mok, J. Boyd, and M. J. Birrer
Choice of Normal Ovarian Control Influences Determination of Differentially Expressed Genes in Ovarian Cancer Expression Profiling Studies
Clin. Cancer Res., October 15, 2003; 9(13): 4811 - 4818.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gregoire, L.
Right arrow Articles by Lancaster, W. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gregoire, L.
Right arrow Articles by Lancaster, W. D.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online